Sunshine Biopharma Inc. announced on Wednesday that it has secured regulatory approval to introduce its generic Enalapril tablets across the Canadian market, marking a strategic step into first-line antihypertensive treatments. The newly approved medication, the generic equivalent of the brand Vasotec, will be available in 2.5mg, 5mg, 10mg, and 20mg tablet strengths. The company currently markets 60 generic prescription drugs in Canada and plans to launch approximately 12 additional drugs during the remainder of 2026. Sunshine Biopharma intends to leverage Nora Pharma Inc., its wholly owned Canadian subsidiary, which has built a wide-reaching distribution infrastructure, with initial shipments to retail pharmacies expected by the close of 2026. The company cited industry data valuing the worldwide antihypertensive drug sector at $25.94 billion in 2025, projected to reach $37.24 billion by 2034 at a 4.1% compound annual growth rate, while the Canadian pharmaceutical market represents about 2.1% of the global industry and ranks as the sixth-largest market.
Sunshine Biopharma IncSecured Canadian regulatory approval to market generic Enalapril, expanding its product portfolio.
